Carsgen's satri-cel granted priority review by the nmpa

Shanghai , may 28, 2025 /prnewswire/ -- carsgen therapeutics holdings limited (stock code: 2171.hk), a company focused on developing innovative car t-cell therapies, announces that the center for drug evaluation (cde) of china's national medical products administration (nmpa) has granted priority review to satricabtagene autoleucel ("satri-cel", ct041)(an autologous car t-cell product candidate against protein claudin18.2), for the treatment of claudin18.2-positive advanced gastric/gastroesophageal junction adenocarcinoma (g/geja) in patients who have failed at least two prior lines of therapy. about satri-cel satri-cel is an autologous car t-cell product candidate against the protein claudin18.2 that has the potential to be the first-in-class globally.
CAR Ratings Summary
CAR Quant Ranking